India stiff-arms CRL app for Bristol-Myers' Sprycel; Adcock board OKs $1.3B takeover by CFR;

@FiercePharma: China's state TV broadcasts corruption allegations against Sino Biopharm, first domestic drugmaker publicly tagged in bribery probe. | Follow @FiercePharma

@CarlyHFierce: Second recall in as many weeks for J&J--this time, a moldy schizophrenia drug is the culprit. More from FiercePharmaManufacturing | Follow @CarlyHFierce

> India's patent office rejected Mumbai-based BDR Pharmaceuticals' application for a compulsory license on Bristol-Myers Squibb's ($BMY) cancer drug Sprycel. Report

> South Africa-based Adcock Ingram said its board approved a $1.3 billion buyout offer from Chile's CFR Pharmaceuticals after CFR pledged to move jobs to South Africa. Report

> Amgen ($AMGN) said researchers found new biomarkers that can predict a lack of response to its cancer treatment Vectibix, which could help target the drug to the right patients. Report

> MiMedx, a company that makes injectable treatments from placental tissue, has drawn scrutiny from the FDA, which questions whether the company's products require more agency oversight. Report (sub. req.)

Medical Device News

@FierceMedDev: Gore's endovascular graft-repair device gains wider FDA nod. Item | Follow @FierceMedDev

@DamianFierce: St. Jude is riding into India with a new pacemaker and a plan to boost sales. Story | Follow @DamianFierce

@MarkHFierce: We have a new round of stories at FierceDiagnostics. Check them out | Follow @MarkHFierce

@MichaelGFierce: ICYMI: Civitas corrals $38M for inhaled Parkinson's treatment. More from FierceDrugDelivery | Follow @MichaelGFierce

> Ariosa targets Brazil with prenatal Dx. Article

> InVivo slides again as CFO bolts, spinal study pends. Report

> J&J feels Decision Diagnostics' sting in glucose strip patent fight. News

Biotech News

@FierceBiotech: ICYMI yesterday--Industry Voices: Breakthrough designation Q&A via Michelle Rohrer. Commentary | Follow @FierceBiotech

@JohnCFierce: I think the patient perspective many news orgs have fundamentally corrupts coverage of animal studies. Article | Follow @JohnCFierce

@EmilyMFierce: Genia Technologies, Columbia, Harvard nab $5.3M NIH grant for genome sequencing. More from FierceBiotech Research | Follow @EmilyMFierce

@Ry_McBride: I'm talking to Treato (social listening for pharma) later today. Stay tuned for post at FierceBiotech IT. | Follow @Ry_McBride

> Gilead leaps ahead with FDA app for PI3K cancer killer. More

> Biotech R&D spending roars ahead as Big Pharma grimly holds the line. Article

> Sanofi cancels diabetes drug pitch--for now--as GLP-1 competition races ahead. Story

> GlaxoSmithKline's great, terrible, wonderful, not-so-good year. Article

Pharma Manufacturing News

@EricPFierce: South Africa's Aspen says manufacturing assets it is getting from GSK, Merck part of global push. Story | Follow @EricPFierce

> J&J recall streak continues with moldy schizophrenia drug. News

> Eisai U.K. site OK'd to make Fycompa. Report

> Merged CFR, Adcock Ingram to have 18 manufacturing sites. Article

> KKR deal in Gland Pharma calls for $100M plant investment. Item

> Pharma packaging growing market with openings for good ideas. More

Vaccines News

> Meningitis cases fall 94% following vaccine introduction. Report

> Low uptake of Merck's Zostavax costing healthcare systems. Item

> Early-phase HIV vaccines advance on positive data. News

> Implant aims to end logistical challenges of cancer vaccines. More

> Pfizer details plans to expand vaccine portfolio beyond Prevnar. Article

> PhIII data dents GSK's hopes for cancer vaccine. Story

And Finally... Middle-aged men need estrogen to fight a spreading waistline, a study found. Report (sub. req.)

Suggested Articles

Pfizer will exit its Perth, Australia sterile injectables manufacturing site by 2024 as part of a global production reorganization effort.

Agios has withdrawn a European application for Tibsovo in AML after the same phase 1 data that earned it an FDA nod failed to impress the EMA.

Sanofi is reportedly considering a sale of some of its anti-inflammation drugs that could snare $234 million as the company pivots toward Dupixent.